

May 9, 2019

Company Name: ONO PHARMACEUTICAL CO., LTD.
 Securities Code: 4528, First Section of the Tokyo Stock Exchange
 Representative: Gyo Sagara, President, Representative Director, and Chief Executive Officer
 Inquiries: Yukio Tani, Corporate Executive Officer, Director, Corporate Communications
public_relations@ono.co.jp

**Notice regarding Differences between Non-Consolidated Results for
 the Fiscal Year Ended March 31, 2019 and Those for the Previous Fiscal Year**

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director, and Chief Executive Officer, Gyo Sagara; “ONO”) announced today that there were differences between its non-consolidated results (Japanese accounting standards) for the fiscal year ended March 2019 (April 1, 2018 to March 31, 2019) and those for the previous fiscal year.

Details

1. Differences between the full-year non-consolidated results for the fiscal year ended March 2019 and those for the previous fiscal year

(Unit: Millions of yen, except basic earnings per share)

	Sales	Operating Profit	Ordinary Profit	Net Profit for the year	Basic earnings per share (yen)
Previous Results (A) (FY ended March 2018)	260,223	45,542	47,155	44,383	85.61
Revised Results (B) (FY ended March 2019)	286,445	57,808	58,292	55,732	108.39
Change (B – A)	26,222	12,266	11,137	11,349	-
Change (%)	10.1	26.9	23.6	25.6	-

2. Reasons for the revision

Because growth in royalty and other revenue contributed to higher sales, there were differences between the full-year non-consolidated results for the fiscal year ended March 31, 2019 and those for the previous fiscal year.